IceCure Medical Q1 2024 Earnings Report $1.08 -0.04 (-3.57%) (As of 11:40 AM ET) Earnings HistoryForecast IceCure Medical EPS ResultsActual EPS-$0.08Consensus EPS -$0.08Beat/MissMet ExpectationsOne Year Ago EPS-$0.08IceCure Medical Revenue ResultsActual Revenue$0.74 millionExpected Revenue$0.80 millionBeat/MissMissed by -$60.00 thousandYoY Revenue GrowthN/AIceCure Medical Announcement DetailsQuarterQ1 2024Date5/28/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseICCM Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Last time you’ll see this priced at $1.00 (Ad)When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!Click here to review Tim’s special Holiday offer before it’s too late. IceCure Medical Earnings HeadlinesData on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual MeetingDecember 16, 2024 | prnewswire.comIcecure Medical: Strong Growth and Regulatory Momentum Support Buy RatingNovember 27, 2024 | markets.businessinsider.comHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.December 27, 2024 | Insiders Exposed (Ad)Icecure Medical’s Strategic Position and Growth Potential Justifies Buy RatingNovember 27, 2024 | markets.businessinsider.comIceCure Medical Sees Strong Growth Amid ProSense® AdoptionNovember 27, 2024 | markets.businessinsider.comIceCure Medical Ltd (NASDAQ:ICCM) Q3 2024 Earnings Call TranscriptNovember 27, 2024 | msn.comSee More IceCure Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IceCure Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IceCure Medical and other key companies, straight to your email. Email Address About IceCure MedicalIceCure Medical (NASDAQ:ICCM), a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.View IceCure Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
